

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ClouDr Group Limited

智雲健康科技集團*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9955)

VOLUNTARY ANNOUNCEMENT IMPROVEMENT OF CLOUDR BRAIN THROUGH INTEGRATION OF DEEPSEEK

This is a voluntary announcement made by ClouDr Group Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”).

The board (the “**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that in February 2025, the Company, as a leader in empowering chronic condition management with digitization, integrated the DeepSeek-R1 model with ClouDr Brain, its proprietary medical artificial intelligence (“**AI**”) to further strengthen the data mining capability of ClouDr Brain and to enhance the efficiency of chronic condition management in the Company’s hospital SaaS and pharmacy SaaS.

The integration of the DeepSeek-R1 model in ClouDr Brain combines advanced data analysis and AI technology to provide precise decision-making support for chronic disease management through big data analysis and machine learning algorithms. Following this integration and by leveraging on the Company’s over one billion electronic health records, the Company’s Cloud GPT and Cloud DTx models will achieve functional upgrades regarding the medical knowledge graph and the clinical decision support system to optimize user experience and improve diagnostic efficiency.

Based on the “2024 AI Large-scale Model Industry Survey and Research Report” published by Business Radio of China National Radio and CCID Consulting Co., Ltd., the Company has been evaluated as one of the market leaders in medical AI industry due to its excellence in both market position and development potential. The integration of the DeepSeek-R1 model in ClouDr Brain will reinforce the Company’s leading position in medical AI industry and accelerate ClouDr Brain’s application in chronic condition management.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
ClouDr Group Limited
Kuang Ming
*Chairman, Executive Director and
Chief Executive Officer*

Hong Kong, February 6, 2025

As at the date of this announcement, the Board comprises Mr. Kuang Ming and Ms. Zuo Yinghui as the executive Directors, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive Directors.

* *For identification purpose only*